ImaginAb and Quibim partner to revolutionize immune status diagnosis and immunotherapy prediction
(Adnkronos) – LOS ANGELES and VALENCIA, Spain, May 2, 2023 /PRNewswire/ — ImaginAb Inc., a global biotechnology company developing 89Zr crefmirlimab berdoxam (CD8 ImmunoPET™) imaging agent and radiopharmaceutical therapies (RPT), and Quibim, a
